Flush on the success of its mRNA vaccine for COVID-19, BioNTech SE is already planning for the next stage of its business life with the acquisition of the neoantigen T-cell receptor (TCR) R&D program and manufacturing plant from Gilead Sciences, Inc.’s Kite Pharma division. The deal is part of a broader expansion of its oncology development program – which has already shown early signs of progress in the clinic – and global manufacturing footprint.
BioNTech Extends Global Reach, Ambition With Kite’s Neoantigen T-Cell Receptor Assets
German Biotech Sets Sights On Cancer Cell Therapies
The company has already expanded into Asia and shown early clinical data from its own cell therapy programs as it acquires Kite Pharma’s neoantigen TCR R&D program and manufacturing plant.
